Abnormal cannabidiol GPR18. Another possible target of abnormal cannabidiol is GPR55, which has also received much attention as a putative cannabinoid receptor, although a growing body of evidence points to lysophosphatidylinositol (LPI) as the endogenous ligand for GPR55. Further research suggests there are yet more additional cannabinoid receptors. Research of the effects on abnormal cannabidiol in mice has indicated that atypical cannabinoids have therapeutic potential in a variety of inflammatory conditions, including those of the gastrointestinal tract. After inducing colitis by means of trinitrobenzene sulfonic acid, wound healing of both human umbilical vein endothelial and epithelial cells was enhanced by the Abn-CBD.
Abnormal profit Abnormal profit persists in the long run in imperfectly competitive markets where firms successfully block the entry of new firms. Abnormal profit is usually generated by an oligopoly or a monopoly; however, firms often try to hide this fact, both from the market and government, in order to reduce the chance of competition, or government intervention in the form of an antitrust investigation. In principle, there are three kinds of abnormal profit: Business writer Michael Porter and Anita M. McGahan undertook an empirical study of the "emergence and sustainability of abnormal profits" in 2003, in which they concluded that both